We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by Yonsei University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00773123
First Posted: October 16, 2008
Last Update Posted: October 16, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Yonsei University
  Purpose
RT-View utilizes spectral domain technology to assess both RNFL and ganglion cell layer thickness. This study aims to correlate visual field defects in patients with glaucoma to both RNFL and ganglion cell layer thickness.

Condition
Primary Open Angle Glaucoma

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Ganglion cell layer thickness [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Visual field defect [ Time Frame: 1 month ]

Estimated Enrollment: 300
Study Start Date: October 2008
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Primary open angle glaucoma
2
Normal controls

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
primary open angle glaucoma
Criteria

Exclusion Criteria:

  • Evidence of retinal disease
  • Neovascular glaucoma
  • Secondary glaucoma due to intraocular inflammation
  • Lens induced glaucoma
  • Tumor induced glaucoma
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00773123


Contacts
Contact: Chan Yun Kim, MD,PhD 82-2-2228-3570 kangeye@hotmail.com
Contact: Sung Yong Kang, MD 82-2-2228-3570 kangeye@yuhs.ac

Locations
Korea, Republic of
Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Chan Yun Kim, MD,PhD    82-2-2228-3570    kangeye@hotmail.com   
Contact: Sung Yong Kang, MD    82-2-2228-3570    kangeye@yuhs.ac   
Principal Investigator: Chan Yun Kim, MD,PhD.         
Sponsors and Collaborators
Yonsei University
  More Information

Responsible Party: Kim,Chan Yun, Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine
ClinicalTrials.gov Identifier: NCT00773123     History of Changes
Other Study ID Numbers: 08-0342
First Submitted: October 15, 2008
First Posted: October 16, 2008
Last Update Posted: October 16, 2008
Last Verified: October 2008

Keywords provided by Yonsei University:
RT-View
Spectral domain OCT
Ganglion cell layer
RNFL
Visual field defect

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases